Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Breckenridge Pharmaceutical has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Methscopolamine Bromide Tablets.
Subscribe to our email newsletter
The company said Methscopolamine Bromide Tablets are AB rated to Pamine, a prescription medicine that is used as adjunctive therapy to treat peptic ulcers.
Pamine is marketed by Kenwood Therapeutics.
The product will hit the market in early 2012.
Breckenridge Pharmaceutical markets more than 70 products in a variety of dosage forms including Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions, and Powders.